Pfizer Vaccine: 100% Efficacy Against Covid-19 in 12-15 Year Olds
Pfizer said the third-stage trial data demonstrated the long-term effectiveness of its vaccine in adolescents aged 12 to 15 years.
The Pfizer Inc announced today that the vaccine against the Covid-19 gave strong long-term protection against the virus in a study last stage held between adolescents from 12-15 years.
Two doses of the vaccine were 100% effective against Covid-19 when their effectiveness was measured from seven days to more than four months after the second dose, the company said.
The long-term data support requests for full approval by the vaccine regulators for this age group in the US and around the world.
Pfizer and BioNTech will request approval for a 30 microgram dose of the vaccine for people 12 years of age and older.
The vaccine was approved in May by the US Food and Drug Administration for emergency use in people aged 12-15 and in August was fully approved for use in people aged 16 and over.
